 pancreatic ductal adenocarcinoma, PDAC, is a highly aggressive form of cancer that has a high mortality rate due to its resistance to traditional treatments such as chemotherapy. Recent research has shown that certain genetic mutations and molecular changes within the tumors can be used to identify which patients would benefit from certain types of targeted therapies. This knowledge could lead to more effective treatments for PDAC patients, increasing their chances of surviving the disease. This article is authored by Hiramitsu Iyashi, Takaki Iigashi, Tatsunori Miyata, and others.